SIRT1 and estrogen signaling cooperation for breast cancer onset and progression

Liarte, Sergio; Alonso-Romero, José Luis; Nicolás, Francisco José

Publication:
SIRT1 and estrogen signaling cooperation for breast cancer onset and progression

dc.contributor.author	Liarte, Sergio
dc.contributor.author	Alonso-Romero, José Luis
dc.contributor.author	Nicolás, Francisco José
dc.contributor.department	Medicina
dc.date.accessioned	2024-11-07T12:36:11Z
dc.date.available	2024-11-07T12:36:11Z
dc.date.issued	2018-09-27
dc.description	© 2018 Liarte, Alonso-Romero and Nicolás. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in Frontiers in Endocrinology. To access the final edited and published work see https://doi.org/10.3389/fendo.2018.00552
dc.description.abstract	Breast cancer remains a significant female mortality cause. It constitutes a multifactorial disease for which research on environmental factors offers little help in predicting onset or progression. The pursuit for its foundations by analyzing hormonal changes as a motive for disease development, indicates that increased exposure to estrogens associates with increased risk. A prevalent number of breast cancer cases show dependence on the increased activity of the classic nuclear estrogen receptor (ER) for cell proliferation and survival. SIRT1 is a Type III histone deacetylase which is receiving increasing attention due to its ability to perform activities over relevant non-histone proteins and transcription factors. Interestingly, concomitant SIRT1 overexpression is commonly found in ER-positive breast cancer cases. Both proteins had been shown to directly interact, in a process related to altered intracellular signaling and aberrant transcription, then promoting tumor progression. Moreover, SIRT1 activities had been also linked to estrogenic effects through interaction with the G-protein coupled membrane bound estrogen receptor (GPER). This work aims to summarize present knowledge on the interplay between SIRT1 and ER/GPER for breast cancer onset and progression. Lastly, evidences on the ability of SIRT1 to interact with TGFß signaling, a concurrent pathway significantly involved in breast cancer progression, are reported. The potential of this research field for the development of innovative strategies in the assessment of orphan breast cancer subtypes, such as triple negative breast cancer (TNBC), is discussed.	es
dc.format	application/pdf	es
dc.format.extent	9	es
dc.identifier.citation	Front. Endocrinol. 9:552
dc.identifier.doi	https://doi.org/10.3389/fendo.2018.00552
dc.identifier.issn	Electronic: 1664-2392
dc.identifier.uri	http://hdl.handle.net/10201/146067
dc.language	eng	es
dc.publisher	Frontiers Media
dc.relation	This work was supported by grants (SAF2006–09482; SAF2003– 06029) from the Spanish Ministry of Education and Science. Also, this work was supported by a grant (PI13/00794) from the Instituto de Salud Carlos III. And the Fondos FEDER Una manera de hacer Europa (ERDF, A way to build Europe). SL received a fellowship from Roche. FN was supported the Fundación para la Formación e Investigación Sanitarias de la Región de Murcia.	es
dc.relation.publisherversion	https://digitum.um.es/digitum/retrieve/654917
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	SIRT1	es
dc.subject	Sex steroids	es
dc.subject	Estrogen receptor	es
dc.subject	GPER	es
dc.subject	Breast cancer	es
dc.subject	TNBC	es
dc.title	SIRT1 and estrogen signaling cooperation for breast cancer onset and progression	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es